Tradestie Institutional Equity Comparison Engine

TAK vs FATE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TAK Overall Edge

TAK Captures Institutional Edge (4โ€“0 Pillars ยท 8โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, TAK trades at 12.7x Forward P/E with 16.6% operating margin (+6.7% YoY revenue) versus FATE at N/M Forward P/E and -1495.4% operating margin (+9.2% YoY). In options structure, TAK sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro) against FATE sits in BREAKDOWN (20th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner TAK
TAK 12.7x vs FATE N/M Fwd P/E
Growth & Margin Winner TAK
Op Margin 16.6% vs -1495.4% ยท YoY +6.7% vs +9.2%
Momentum & Technical Winner TAK
1Y +51.8% vs +12.9% ยท 52W Pos 97% vs 8%
Options & Structure Winner TAK
UNCLASSIFIED (5th %ile IV) vs BREAKDOWN (20th %ile IV)
TAK NYSE
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
1M Return +9.89%
1Y Return +51.79%
Forward P/E 12.7x
Unified AI Score
47.7 / 100 HOLD
Tech 42.0 Fund 43.0 Flow 50.0 Mom 40.0
FATE NASDAQ
Fate Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$1.12
-12.5% 1D
Market Cap $162.9M
1M Return -37.43%
1Y Return +12.87%
Forward P/E N/M
Unified AI Score
41.9 / 100 SELL
Tech 25.0 Fund 47.0 Flow 67.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: TAK +51.79% FATE +12.87% Spread: +38.92 pp (TAK Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
TAK TTM Op. Margin: 16.6% FATE TTM Op. Margin: -1495.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs FATE. Trailing 12-month operating profitability (TAK 16.6% vs FATE -1495.4%) and valuation multiples (TAK 12.7x vs FATE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: TAK (8) vs FATE (1)
Institutional Metric TAK FATE Criterion Row Winner
Market Capitalization Scale $67.5B $162.9M Larger Scale TAK
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation 12.7x N/M Lower Multiple TAK
Revenue Growth (YoY) Growth +6.7% +9.2% Higher Growth FATE
Operating Margin (TTM) Profitability 16.6% -1495.4% Higher Margin TAK
Net Profit Margin Profitability 0.9% 0.0% Higher Margin TAK
Return on Equity (ROE) Capital Efficiency 0.6% -60.8% Higher ROE TAK
52-Week Range Position Momentum 97% ($14โ€“$22) 8% ($1โ€“$3) Stronger Trend TAK
Beta / 30D Volatility Risk Regime -0.02ฮฒ ยท 22% Vol 2.16ฮฒ ยท 104% Vol Lower Realized Risk TAK
Unified Institutional Score Composite Signal 47.7 / 100 (HOLD) 41.9 / 100 (SELL) Higher Composite TAK

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full TAK vs FATE Buy Guide
TAK UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 5th %ile
IV Regime Compressed (<25th %ile)
Live TAK Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
FATE BREAKDOWN
118d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 20th %ile
IV Regime Compressed (<25th %ile)
Live FATE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither TAK nor FATE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.